Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibito...
Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review)
About this item
Full title
Author / Creator
Publisher
Greece: Spandidos Publications
Journal title
Language
English
Formats
Publication information
Publisher
Greece: Spandidos Publications
Subjects
More information
Scope and Contents
Contents
Poly (ADP‑ribose) polymerase (PARP) inhibitors, including olaparib, niraparib, rucaparib, talazoparib and veliparib, have emerged as one of the most exciting new treatments for solid tumors, particularly in patients with breast‑related cancer antigen 1/2 mutations. Oral administration is convenient and shows favorable compliance with the majority o...
Alternative Titles
Full title
Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review)
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2601483584
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2601483584
Other Identifiers
ISSN
1021-335X,1791-2431
E-ISSN
1791-2431
DOI
10.3892/or.2021.8231
